We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Trovagene is a clinical-stage oncology therapeutics company, developing drugs that target mitosis (cell division) and integrating a biomarker approach to identifying patient most likely to respond to treatment. Currently, 3 clinical trials are underway with lead drug candidate, Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1(PLK1) inhibitor: a Phase 1b/2 trial of Onvansertib in combination with standard-of-care chemo in Acute Myeloid Leukemia (AML); a Phase 2 trial of Onvansertib in combination with Zytiga in metastatic Castration-Resistant Prostate Cancer (mCRPC; and a Phase 1b/2 trial of Onvansertib in combination with FOLFIRI and Avastin in metastatic Colorectal Cancer (mCRC).